Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug’s (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine.

SecureDose is reportedly initiating work on a novel manufacturing method for the commercial-scale production of cocaine, which will be produced to support safe supply programs.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

“We have seen the proliferation of safe supply programs in both Canada and around the world. While opioid addiction is a serious problem, there exists a supply chain that provides both natural and synthetic opioid products for those programs,” commented Robert Steen, CEO of PharmaDrug.

“Cocaine, however, is the illegal drug that causes the most cost and harm to society barring opioids according to the Canadian Centre for Substance Use and Addiction, causing $4.2 Billion1 in harm in Canada annually – but there is no supply chain to alleviate these harms.”

READ: PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

A patent has been filed for a method of development that uses biosynthetic chemistry that the company believes will allow for the use of GMP manufacturing in the production of pharmaceutical grade cocaine. The intent is that the resulting product will be a reliable, regulated, clinically manufactured product that is suitable for use in safe supply programs.

A lab has already been identified by the company that will be used for the development of the novel process. An accelerated development timeframe is being pursued by the lab, with the manufacturing process to target the cost effective and efficient production of cocaine.

PharmaDrug last traded at $0.06 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Cambria Gold Drills 166 g/t Gold and 3,383 g/t Silver Over 3.1 Metres at Premier

Selkirk Copper’s Minto PEA Outlines $494 Million After-Tax NPV and 47.8% IRR

Related News

PharmaDrug Subsidiary Begins Prep Work For Clinical Trial Of PD-001 For Viral Infectious Diseases

PharmaDrug (CSE: PHRX) yesterday reported that its joint venture, Sairiyo Therapeutics, has begun the process...
Friday, September 20, 2024, 08:29:02 AM

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM

PharmaDrug Engages Research Lab To Advance Patented Cocaine Synthesis Method

PharmaDrug (CSE: PHRX) has formally engaged a research lab to refine and advance the development...
Tuesday, April 16, 2024, 09:31:23 AM

PharmaDrug: A Path To Safe Supply

In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company's groundbreaking biosynthetic...
Wednesday, March 13, 2024, 01:30:00 PM

PharmaDrug’s Sairiyo To Begin Manufacturing PD-001 For Clinical Trials In Q2

PharmaDrug (CSE: PHRX) has seen its joint venture with PharmaTher Holdings (CSE: PHRM) begin to...
Wednesday, February 14, 2024, 09:46:59 AM